HealthLynked Corp. HLYK

Q2 FY2026 · ended Jun 30, 2026 · Revenue $249,830, -57.8% YoY · Filed Aug 14, 2026

HealthLynked Corp. (HLYK) files with the SEC under industry code 8011, Services-Offices & Clinics of Doctors of Medicine. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $249,830 and a net loss of $819,705. As of Jun 30, 2026 it held $12,844 in cash and investments and $9,715 in total debt.

Revenue
$249,830
-57.8% vs year-ago quarter
Net income
$-819,705
-16.9% vs year-ago quarter
Operating cash flow
$-350,133
+16.1% vs year-ago quarter
Free cash flow
$-743,602
+28.3% vs prior quarter
EPS
$-0.28
-12.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.95M
-99.0% vs year-ago quarter
Net cash
$3,129
Q2 FY2026
Operating margin
-167.6%
TTM

Company profile

Industry
Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
Listed as
HLYK (OTC)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Naples, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1680139

Other Services-Offices & Clinics of Doctors of Medicine companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Line
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Revenue
$249,830
$423,465
$310,179
$388,545
$592,360
Operating income
-$538,776
-$700,813
-$530,894
-$529,586
-$435,385
Net income
-$819,705
-$1.6M
-$676,477
-$851,800
-$701,038
Diluted EPS
-$0.28
-$0.56
-$0.24
-$0.30
-$0.25
Operating cash flow
-$350,133
-$221,976
-$419,430
-$444,291
-$417,536
Total assets
$1.6M
$1.6M
$1.7M
$1.8M
$1.8M
Total liabilities
$9.3M
$8.6M
$7.5M
$7.2M
$6.6M
Stockholders' equity
-$7.8M
-$7.0M
-$5.8M
-$5.4M
-$4.8M
Cash and investments
$12,844
$23,973
$37,136
$10,911
$20,201
Total debt
$9,715
$37,789
$76,090
$120,433
$153,813

Recent SEC filings

Recent SEC filings
Form Description Filed Period
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
8-K Current report
Officer or director change
Jul 16, 2026 Jul 13, 2026
10-Q Quarterly report May 15, 2026 Mar 31, 2026
10-K Annual report Mar 31, 2026 Dec 31, 2025
8-K Current report
Material agreement, New debt, Unregistered share sale
Feb 6, 2026 Feb 2, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
Dec 12, 2025 Dec 1, 2025

Source: SEC EDGAR filings. This is company-reported data, not investment advice.